in vivo News and Research

RSS

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Researchers in UCD Conway Institute and Systems Biology Ireland have identified a way that a new class of anti-inflammatory drugs may be used to treat inflammatory bowel disease (IBD).

7 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

Reinnervate, Oncotest and SBH partner to offer 3D tumour cell screening services

3D cell culture company Reinnervate Ltd today announced partnerships with two oncology-focussed CRO's to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models.

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

UCR, CRF initiate PROSPECT II trial to identify plaques that may lead to coronary events

The Cardiovascular Research Foundation (CRF) of New York, NY and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced today the initiation of the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) II trial and the PROSPECT ABSORB sub study.

29 Oct 2013

UMMS professor receives EUREKA grant to develop light activated nanoparticles for imaging brain tissue

University of Massachusetts Medical School Assistant Professor of Biochemistry and Molecular Pharmacology Gang Han, PhD, has received a $1.3 million EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration) grant from the National Institute of Mental Health to develop light activated nanoparticles that can be used to image live brain tissue.

25 Oct 2013

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

New technological approach may help improve stem cell-based neurodegenerative diseases

An international research group has successfully tested the use of a new type of porous material for the efficient delivery of key molecules to transplanted cells derived from stem cells. These results can lead to improvements in the way stem cell-based neurodegenerative diseases are treated.

23 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Scientists find that activating family of small protein could suppress liver malignancies

A team of scientists from the National University of Singapore (NUS) has found that activating a family of small protein, known as Rho, could suppress liver malignancies.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body.

19 Oct 2013

Study shows narrow-spectrum UV light reduces surgical infections without damaging tissue

Despite major efforts to keep operating rooms sterile, surgical wound infections remain a serious and stubborn problem, killing up to 8,200 patients a year in the U.S. A study by Columbia University Medical Center (CUMC) researchers suggests that narrow-spectrum ultraviolet (UV) light could dramatically reduce such infections without damaging human tissue.

17 Oct 2013

Discovery of neural firing-rate set point opens door to possible treatment for devastating disorders

As we learn and develop, our neurons change. They make new pathways and connections as our brain processes new information. In order to do this, individual neurons use an internal gauge to maintain a delicate balance that keeps our brains from becoming too excitable.

17 Oct 2013

New $1.9M research grant to support investigators to detect tumors in earliest stages of formation

The National Cancer Institute's new Provocative Questions research funding program has awarded a prestigious grant to researchers at the Case Comprehensive Cancer Center and Case Western Reserve University's Schools of Medicine and Engineering to study tumor detection at the earliest stages of growth.

16 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Cdk5 protein may play crucial role in deadly form of thyroid cancer

A specific protein once thought to exist only in the brain may play a crucial role in a deadly form of thyroid cancer, as well as other cancers, and provide a fresh target for researchers seeking ways to stop its progression, UT Southwestern Medical Center researchers report today in Cancer Cell.

15 Oct 2013

Scientists develop new method to regenerate cartilage

Unlike our bones, the cartilage inside our joints is not vascularized (i.e., it has no blood vessels). This is one reason why cartilage does not heal well after an injury. In athletes in particular, joint injuries often result in cartilage degeneration and arthritis. The process is chronic and irreversible, and to this day, no effective treatment exists.

12 Oct 2013

CHD Bioscience's lead product can help mitigate increasing threat of HAIs

According to a recent report issued by the Centers for Disease Control, every year more than two million people develop infections that are resistant to antibiotics. Specific healthcare-associated infections are classified as urgent threats and affect approximately 1.7 million people annually across the United States, leading to death in nearly 99,000 patients.

9 Oct 2013

ERK pathway discovery may provide therapeutic options for treating drug addictions

The extracellular-signal regulated kinase (ERK) pathway plays a role in multiple drug addictions and appears to modulate neuronal plasticity through epigenetic mechanisms, say French scientists.

7 Oct 2013

in vivo News and Research

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Reinnervate, Oncotest and SBH partner to offer 3D tumour cell screening services

Immune Design closes Series C financing totalling up to $49M

UCR, CRF initiate PROSPECT II trial to identify plaques that may lead to coronary events

UMMS professor receives EUREKA grant to develop light activated nanoparticles for imaging brain tissue

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

New technological approach may help improve stem cell-based neurodegenerative diseases

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Scientists find that activating family of small protein could suppress liver malignancies

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

Study shows narrow-spectrum UV light reduces surgical infections without damaging tissue

Discovery of neural firing-rate set point opens door to possible treatment for devastating disorders

New $1.9M research grant to support investigators to detect tumors in earliest stages of formation

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Cdk5 protein may play crucial role in deadly form of thyroid cancer

Scientists develop new method to regenerate cartilage

CHD Bioscience's lead product can help mitigate increasing threat of HAIs

ERK pathway discovery may provide therapeutic options for treating drug addictions

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News